{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:22:48Z","timestamp":1786753368058,"version":"build-2736575974"},"reference-count":36,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA233562"],"award-info":[{"award-number":["R01 CA233562"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA237272"],"award-info":[{"award-number":["R01 CA237272"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Andy North and Friends","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast activation protein (FAP) is an attractive target for the development of cancer theranostics due to its selective expression on cancer-associated fibroblasts (CAFs). While a number of small-molecule FAP inhibitors (FAPIs) have been developed, few biologics have been investigated as FAP-targeting vectors. Camelid-derived single-domain antibodies, or variable-heavy-heavy domains (VHHs), offer a compelling alternative, combining high affinity with versatile engineering options. In this study, we first identified a novel anti-FAP VHH, F7, from an affinity-matured camelid phage display library. To investigate how valency and molecular weight affected target engagement and in vivo properties, F7 was engineered into three formats: a monomer (F7), a tethered dimer (F7D), and an Fc-fusion protein (F7-Fc). All three were specific for FAP with the two bivalent constructs demonstrating picomolar affinity. Positron emission tomography imaging in FAP-positive xenograft models revealed distinct pharmacokinetic profiles across constructs, with notable differences in tumor uptake and clearance. F7 had rapid uptake and clearance, resulting in significantly higher tumor uptake than FAPI-46. Low molecular weight bivalent F7D demonstrated similar kinetics but was retained by the tumor, resulting in a high tumor-to-blood ratio with secondary uptake limited to clearance organs. The largest construct, F7-Fc, resulted in the highest tumor uptake and allowed for longitudinal imaging. Absorbed dose calculations confirmed that tumors received significantly higher radiation doses compared to normal tissues. These findings demonstrate that tuning VHH scaffold size and valency can improve biodistribution and retention, establishing F7-based constructs as promising targeting vectors for FAP.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00238","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:05:59Z","timestamp":1784628359000},"page":"4181-4189","source":"Crossref","is-referenced-by-count":1,"title":["Tuning\nthe Structural Properties of a Single-Domain\nAntibody Scaffold for Improved Fibroblast Activation Protein Targeting"],"prefix":"10.1021","volume":"23","author":[{"given":"Joseph P.","family":"Gallant","sequence":"first","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]},{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendahl L.","family":"Ott","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]},{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohyun","family":"Kwon","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adedamola","family":"Adeniyi","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall E.","family":"Barrett","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Rosenkrans","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Mixdorf","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Aluicio-Sarduy","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]},{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health , , ,","place":["Madison, Wisconsin, United States, 53792"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-7228","authenticated-orcid":true,"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-2179","authenticated-orcid":true,"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]},{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53792"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Bednarz","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3802-7789","authenticated-orcid":true,"given":"Aaron M.","family":"LeBeau","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53705"]},{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health , , ,","place":["Madison, Wisconsin, United States, 53792"]},{"name":"University of Wisconsin School of Medicine and Public Health , , , ,","place":["Madison, Wisconsin, United States, 53792"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"3","key":"2026080309080091800_cit1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health\nand malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"2026080309080091800_cit2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or\nopportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"2026080309080091800_cit3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The Latest Developments\nin Imaging\nof Fibroblast Activation Protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"32","key":"2026080309080091800_cit4","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein\nin cancer: back to the basics","volume":"37","author":"Pure\u0301","year":"2018","journal-title":"Oncogene"},{"issue":"2","key":"2026080309080091800_cit5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-11-0340","article-title":"Rationale behind targeting fibroblast\nactivation protein-expressing carcinoma-associated fibroblasts as\na novel chemotherapeutic strategy","volume":"11","author":"Brennen","year":"2012","journal-title":"Mol. Cancer\nTher."},{"key":"2026080309080091800_cit6","doi-asserted-by":"publisher","first-page":"648187","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast Activation\nProtein-alpha as a Target\nin the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative\nReview","volume":"11","author":"Xin","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"2026080309080091800_cit7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.advms.2015.04.006","article-title":"Specific inhibition\nof fibroblast activation protein (FAP)-alpha prevents tumor progression\nin vitro","volume":"60","author":"Teichgra\u0308ber","year":"2015","journal-title":"Adv. Med. Sci."},{"issue":"6","key":"2026080309080091800_cit8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/1078-0432.CCR-06-1746","article-title":"Clinical Implications\nof Fibroblast Activation Protein in Patients with Colon Cancer","volume":"13","author":"Henry","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6005","key":"2026080309080091800_cit9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor\nimmunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"issue":"4","key":"2026080309080091800_cit10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment\nin immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"issue":"6","key":"2026080309080091800_cit11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/2767-9764.CRC-24-0248","article-title":"Mechanistic Characterization\nof Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate\nTargeting Fibroblast Activation Protein","volume":"4","author":"Gallant","year":"2024","journal-title":"Cancer\nRes. Commun."},{"issue":"10","key":"2026080309080091800_cit12","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/s41416-024-02639-1","article-title":"Fibroblast\nactivation\nprotein-targeted near-infrared photoimmunotherapy depletes immunosuppressive\ncancer-associated fibroblasts and remodels local tumor immunity","volume":"130","author":"Akai","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"2","key":"2026080309080091800_cit13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00018-002-8427-5","article-title":"The prolyl\noligopeptidase family","volume":"59","author":"Polgar","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"issue":"D1","key":"2026080309080091800_cit14","doi-asserted-by":"publisher","first-page":"D503","DOI":"10.1093\/nar\/gkt953","article-title":"MEROPS: the database\nof proteolytic enzymes, their substrates and inhibitors","volume":"42","author":"Rawlings","year":"2014","journal-title":"Nucl Acids Res."},{"issue":"1","key":"2026080309080091800_cit15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1074\/jbc.RA118.004254","article-title":"Carboxypeptidase in\nprolyl oligopeptidase family: Unique enzyme activation and substrate-screening\nmechanisms","volume":"294","author":"Yadav","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"20","key":"2026080309080091800_cit16","doi-asserted-by":"publisher","first-page":"19441","DOI":"10.1074\/jbc.C500092200","article-title":"Structural and kinetic\nanalysis of the substrate specificity of human fibroblast activation\nprotein alpha","volume":"280","author":"Aertgeerts","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"5","key":"2026080309080091800_cit17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-08-1170","article-title":"Targeting the cancer\nstroma with a fibroblast activation protein-activated promelittin\nprotoxin","volume":"8","author":"LeBeau","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"2026080309080091800_cit18","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure-activity\nrelationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine\ninhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026080309080091800_cit19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2967\/jnumed.123.266345","article-title":"Preclinical Development\nof PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-alpha\n(FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive\nTumors","volume":"65","author":"Poplawski","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"8015","key":"2026080309080091800_cit20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide\ntherapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"1","key":"2026080309080091800_cit21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications\nof fibroblast activation protein inhibitor positron emission tomography\n(FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"Npj Imaging"},{"issue":"10","key":"2026080309080091800_cit22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2967\/jnumed.124.267923","article-title":"1,090 Publications\nand 5 Years Later: Is FAP-Targeted Theranostics Really Happening?","volume":"65","author":"Haberkorn","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026080309080091800_cit23","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s42003-025-08610-x","article-title":"The characterization\nof variable new antigen receptors targeting FAP isolated from a novel\nimmunized library","volume":"8","author":"Gunaratne","year":"2025","journal-title":"Commun. Biol."},{"key":"2026080309080091800_cit24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ebiom.2016.04.028","article-title":"Nanobodies as Versatile Tools to\nUnderstand, Diagnose, Visualize and Treat Cancer","volume":"8","author":"Van Audenhove","year":"2016","journal-title":"EBioMedicine"},{"key":"2026080309080091800_cit25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications\nof Nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Annu. Rev. Anim. Biosci."},{"issue":"8","key":"2026080309080091800_cit26","doi-asserted-by":"publisher","first-page":"107502","DOI":"10.1016\/j.jbc.2024.107502","article-title":"Identification and biophysical\ncharacterization of a novel domain-swapped camelid antibody specific\nfor fentanyl","volume":"300","author":"Gallant","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2026080309080091800_cit27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antib8010013","article-title":"Nanobody Engineering:\nToward Next Generation Immunotherapies\nand Immunoimaging of Cancer","volume":"8","author":"Chanier","year":"2019","journal-title":"Antibodies"},{"issue":"4","key":"2026080309080091800_cit28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/cbr.2018.2451","article-title":"Development\nand Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional\nInternal Dosimetry Platform","volume":"33","author":"Besemer","year":"2018","journal-title":"Cancer Biother.\nRadiopharm."},{"issue":"3","key":"2026080309080091800_cit29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1021\/acs.bioconjchem.4c00019","article-title":"Development of an Engineered\nSingle-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer","volume":"35","author":"Luo","year":"2024","journal-title":"Bioconjugate Chem."},{"key":"2026080309080091800_cit30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64815","article-title":"The development\nof Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates","volume":"10","author":"Ye","year":"2021","journal-title":"Elife"},{"issue":"18","key":"2026080309080091800_cit31","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive\nstromal fibroblasts as a potential antibody target in human epithelial\ncancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"2026080309080091800_cit32","first-page":"3327","article-title":"Regulation and heteromeric\nstructure of the fibroblast activation protein in normal and transformed\ncells of mesenchymal and neuroectodermal origin","volume":"53","author":"Rettig","year":"1993","journal-title":"Cancer Res."},{"issue":"9","key":"2026080309080091800_cit33","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1016\/j.apsb.2025.07.009","article-title":"Fibroblast activation\nprotein targeting radiopharmaceuticals: From drug design to clinical\ntranslation","volume":"15","author":"Wu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"21","key":"2026080309080091800_cit34","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.3390\/cancers17213412","article-title":"Radioligand Therapy in Cancer Management:\nA Global Perspective","volume":"17","author":"Ninatti","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"2026080309080091800_cit35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/17460441.2022.2034783","article-title":"Electrophilic warheads\nin covalent drug discovery: an overview","volume":"17","author":"Peczka","year":"2022","journal-title":"Expert\nOpin. Drug Discovery"},{"issue":"6","key":"2026080309080091800_cit36","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel\nGeneration of\nFAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00238","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4181\/66080883\/acs.molpharmaceut.6c00238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4181\/66080883\/acs.molpharmaceut.6c00238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:16:39Z","timestamp":1785762999000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4181\/5224234\/Tuning-the-Structural-Properties-of-a-Single"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,21]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00238","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}